QSAM Biosciences, Inc. (OTCQB: QSAM)

Next Generation Nuclear Technology Focused on the Eradication of Cancer

Management believes its initial technology, CycloSam® has a strong pathway to commercialization in a Global Market Size that is valued at $12.6 Billion*

Company Summary:

QSAM Biosciences, Inc. (OTCQB: QSAM), is developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions.

QSAM’s initial technology is CycloSam® (Samarium-153 DOTMP), a clinical-staged bone targeting radiopharmaceutical that is cleared by the FDA under an investigator IND to commence human dosing immediately in patients with osteosarcoma and bone metastasis.

Key Metrics @ 12/21/2020

Closing Price $0.51
52 Week Range $0.20 to $0.875
Shares Outstanding 17.841M
Shares in the Float 14.890M
Held @ DTC 1.795M
Shares Authorized 300M
Average Daily Volume: (Last 5 Days) 29,140
Market Cap $9.455M
Reporting Status SEC Reporting
Financials Audited
Most Recent Filing: 10-Q  for 09/30/2020 Filed:  11/23/2020
Fiscal Year-end 12/31

(Source: OTC Markets, Yahoo Finance, SEC filings)

Corporate News:

Palm Beach, FL, Dec. 10, 2020 (GLOBE NEWSWIRE) — QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Cyclosam® Samarium-153-DOTMP, for the treatment of cancer and related diseases and conditions, announced today that the European Patent Office (EPO) has allowed the first patent covering “DOTMP kit formulations for radioisotopes.”

This is the first patent outside the United States and is in addition to the two prior patents issued by the United States Patent & Trademark Office (USPTO) covering “High purity and low specific activity therapeutic bone agents.”

The EPO patent allowance covers technology licensed exclusively by QSAM from IGL Pharma, Inc. that protects the radiopharmacy preparation of CycloSam. The DOTMP kits, which refer to the chelating agent that binds the radioisotopes to growing cells in the bone and is believed by management to reduce toxicity and increase efficacy of the drug candidate, are a crucial component of the Cyclosam radiopharmaceutical product.

Click on the above link to read the full press release.

Pharmaceutical Industry Experts Assume Leadership Roles at QSAM;
Over $4M in Debt Eliminated from Balance Sheet

Palm Beach, FL, Nov. 10, 2020 (GLOBE NEWSWIRE) — QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Omnibus Separation Agreement with Earth Property Holdings LLC (“EPH”) to provide for the termination of management services to EPH and the elimination of over $1.1 million in debt owed to EPH, among other terms.

In connection with this agreement, Kevin Bolin has stepped down as Chairman and CEO of the Company and has been replaced by Douglas Baum as CEO and C. Richard Piazza as Executive Chairman of the Board.

In separate transactions, the Company has also converted approximately $2.8 million in promissory notes previously in default, and approximately an additional $0.37 million in deferred compensation and other liabilities, into shares of common stock at a conversion price of $0.22 per share.

Click on the above link to read the full press release.

Palm Beach, FL, Oct. 09, 2020 (GLOBE NEWSWIRE) –QSAM Biosciences, Inc. announced today that it has commenced trading on The OTC Markets under the new stock symbol QSAM.

Last month QSAM announced its new name and business direction pursuing the development and commercialization of a clinical stage novel radiopharmaceutical called CycloSam® which is meant to treat different types of bone cancer and related diseases.

QSAM has worldwide, exclusive rights to this promising nuclear technology. CycloSam is expected to go into Phase 1 clinical trials in Q1 2021, and has already been used successfully in one human trial this past summer.

“This is another step forward in our corporate development, which should be matched over the next several months with important advancements preparing for human trials of CycloSam, and developing strategic partnerships that can help us on our mission to treat bone cancer,” stated Douglas Baum, a company Director and President and CEO of the company’s wholly subsidiary QSAM Therapeutics.

Click on the above link to read the full press release.

Key Investment Considerations:

  • Management: “You will not find a management team of this caliber in any other small cap company with a $7 million market cap.” (OTC Stock Review)
  • CycloSam® has already demonstrated safety and efficacy in animal studies and a human trial performed at the prestigious Cleveland Clinic and is cleared by the FDA under an investigator IND to commence human dosing immediately in patients with osteosarcoma and bone metastasis. 
  • Initial research has identified four initial potential indications for CycloSam®: Osteosarcoma (bone cancer); Metastatic Bone Cancers; Bone Marrow Ablation (removal); Lower Dose Radiation.
  • Executive Leadership and Advisory Team has extensive domain as well as FDA application/approval process experience.
  • QSAM shares are significantly undervalued compared to other companies in the FDA approval process. (Penny Stocks News)

Bottom Line Observation:

QSAM has seen a quick upward movement from $0.21/share on 11/17/2020 to $0.51 in the last month as news about the Company’s singular focus on CycloSam® has made its way around the street, its recently improved balance sheet, and its recently awarded European patent that protects the radiopharmacy preparation of CycloSam.

This is just the beginning of what looks like a ground floor opportunity for bio-tech/bio-science investors and a high upward movement in share price.

Here’s what the new CEO, Richard Baum had to say:

With the elimination of a significant amount of our debt and the laser focus we can now apply to developing our promising drug candidate, I believe we are in a position to raise long term capital that will help fast track the growth of QSAM and build value for our shareholders by funding and aggressively pursuing CycloSam FDA approval.”

Interested investors definitely want to keep QSAM on their radar screens or even start building a position in the shares at what appears to be a nice entry point.

Research and Editorial Staff of MicroCap MarketPlace

_________________________________________________________________________

More about QSAM Biosciences, Inc. (OTCQB: QSAM)

QSAM Biosciences, Inc. (f/k/a) Q2Earth, Inc.) is developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions.

QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam®, a clinical-staged bone targeting radiopharmaceutical​ from IsoTherapeutics Group, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation.

CycloSam® has already demonstrated safety and efficacy in animal studies and a human trial performed at the prestigious Cleveland Clinic. This drug candidate utilizes an FDA approved radioisotope combined with a novel chelate that has demonstrated increased efficacy and decreased side effects in animal models.

Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process. Given these factors, management believes there is a strong pathway to commercialization.

CycloSam® is cleared by the FDA under an investigator IND to commence human dosing immediately in patients with osteosarcoma and bone metastasis. CycloSam® was also cleared by FDA and successfully used under a single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T) in 2020.

Interested investors can find out more about QSAM Biosciences, Inc. and the Company’s wholly-owned subsidiary, QSAM Therapeutics, Inc. by visiting https://qsambio.com/

__________________________________________________________________________

*Nuclear Medicine Market Size Worth $12.6 Billion by 2027 | CAGR 9.5%

February 2020 | Report Format: Electronic (PDF) The global nuclear medicine market size is expected to reach USD 12.6 billion by 2027, expanding at a CAGR of 9.5%, according to a new report by Grand View Research, Inc. Research and development of advanced technologies by the key players for diagnosis and treatment of diseases is expected to drive the radiopharmaceuticals market.

__________________________________________________________________________

Disclaimer and Disclosures: MicroCap MarketPlace (MCMP) is a financial publisher and not a FINRA broker/dealer or investment adviser. MCMP is not registered with the SEC / U.S. Securities and Exchange Commission or any state securities regulatory agency. Readers, subscribers and web site visitors are responsible for individual investment decisions. All information contained in our newsletters or on our web site and in our blogs should be independently verified with the featured companies and readers should always conduct their own research and due diligence and engage professional investment advisers as they deem appropriate before making investment decisions. Please review the Terms and Conditions of Use, including without limitation all disclaimers of warranties and limitations on liability contained therein. Your use of any information on our websites, contained herein or in our newsletters and blogs constitutes your agreement of same. Officers, employees and affiliates may hold positions in the featured securities discussed in our newsletters or on our web site and blogs and may buy or sell said securities at any time without further notice. MCMP and/or affiliates may from time to time receive cash and/or equity compensation from featured companies for corporate marketing and communications services. In the interest of full disclosure, Mike Casson, MCMP’s Founder/Executive Editor is also president of Casson Communications, LLC (CCLLC) an affiliated company. CCLLC has received five thousand dollars in cash compensation for marketing and communication services and allocated a portion of that compensation for the distribution of this article as part of said services. You should be aware of these potential conflicts of interest. We believe the information contained herein and in our publications to be reliable but cannot guarantee its accuracy; therefore, all information is provided as is without warranty of any kind. Past results are not necessarily indicative of future performance.

© 2020 MicroCap MarketPlace, All Rights Reserved